Spotlight
Topics
DI Executive
Subscribe
- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
SNMMI: New Study Suggests Merits of FAPI PET/CT for Breast Cancer Staging
Improved assessment of axillary lymph node status with FAPI PET/CT led to restaging of nearly 71 percent of patients with breast cancer, according to new research presented at the SNMMI 2024 conference.
Can fibroblast activation protein inhibitor (FAPI) PET/CT have an impact in staging for women with newly diagnosed breast cancer?
For the study, which was presented at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, researchers compared clinical TNM staging between FAPI PET/CT and 18F-FDG PET/CT, which is commonly utilized in breast cancer staging. The cohort was comprised of 121 women with breast cancer. According to the study, 53 women had 68Ga-FAPI-04 PET/CT, 68 study participants had A118F-FAPI-04 PET/CT and all patients had 18F-FDG PET/CT scans.
The researchers found that FAPI PET/CT, in comparison to TNM staging with 18F-FDG PET/CT, restaged 19.8 percent of patients (24/121). Assessment of axillary lymph node (ALN) status by FAPI PET/CT was a significant factor for 17 of 24 patients (70.8 percent) who had TNM restaging, according to the study authors.
New research presented at the SNMMI 2024 conference found that FAPI PET/CT, in comparison to TNM staging with 18F-FDG PET/CT, restaged 19.8 percent of patients (24/121) with newly diagnosed breast cancer,
Noting the challenges with 18F-FDG PET/CT with respect to reduced sensitivity in certain breast cancer subtypes and false positives with inflammatory breast lesions, the researchers said the study findings show that FAPI PET/CT can be a viable alternative.
“This study is significant as it has the potential to advance personalized treatment strategies for breast cancer patients,” noted lead study author Zhixin Hao, M.D., a nuclear medicine physician affiliated with Peking Union Medical College Hospital in Beijing, China. “FAPI PET/CT for the initial staging of breast cancer has the potential to reduce unnecessary treatments and improve patient outcomes.”
The researchers also pointed out that FAPI PET/CT down-staged 20.6 percent of women (7/34) with initial IIB staging andupstaged 21.7 percent of patients (10/46) with initial IIA staging.
“Patients with stage IIA (breast cancer) should be considered for systemic staging with FAPI PET/CT at the time of initial diagnosis,” emphasized Hao and colleagues.
Reference
1. Hao Z, Pan B, Yao R, Zhou Y, Sun Q, Huo L. FAPI versus 18F-FDG PET/CT for systemic staging of newly diagnosed breast cancer. Presented at the 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting, June 8-11, Toronto, Canada. Available at: https://www.xcdsystem.com/snmmi/program/10OD8Tq/index.cfm . Accessed June 11, 2024.
Recent Videos
Related Content
Mammography Study Suggests DBT-Based AI May Help Reduce Disparities with Breast Cancer Screening
December 13th 2024Article
New research suggests that AI-powered assessment of digital breast tomosynthesis (DBT) for short-term breast cancer risk may help address racial disparities with detection and shortcomings of traditional mammography in women with dense breasts.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024Article
In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
Assessing MACE Risk in Women: Can an Emerging Model with SPECT MPI Imaging Have an Impact?
December 9th 2024Article
In research involving over 2,200 women who had SPECT MPI exams, researchers found that those who had a high score with the COronary Risk Score in WOmen (CORSWO) model had a greater than fourfold higher risk of major adverse coronary events (MACE).
